Lanreotide

Therapeutic

treatment of neuroendocrine tumours and acromegaly.

Structural features

SMILES

[H]N([H])CCCCC1N([H])C(=O)C(CC2=CN([H])C3=CC=CC=C23)N([H])C(=O)C(CC2=CC=C(O)C=C2)N([H])C(=O)C(CSSCC(N([H])C(=O)C(N([H])C1=O)C(C)C)C(=O)N([H])C(C(C)O)C(=O)N([H])[H])N([H])C(=O)C(CC1=CC2=CC=CC=C2C=C1)N([H])[H]

Sequence

XCYwKVCT-NH2

Molar mass

1096.33 g/mol

Constitutional members:

8

Natural amino acids

6

D-Amino acids

2

N-terminus

H

C-terminus

NH2

Cyclic

yes

Members/cycle

6

Bond to form cycle

side chain-to-side chain (disulfide)

Lipidation

no

Glycosylation

no

Route of administration

SC

Terminal half-life

22 days

Protein binding

-

Absorption and Bioavailability

Lanreotide forms a drug depot at the site of injection; therefore, there are 2 phases that describe the absorption of Lanreotide: 1. Initial rapid subcutaneous release during the first few days of treatment where drug that has not precipitated is rapidly absorbed. 2. Slow release of drug from the depot via passive diffusion. Absorption is independent of body weight, gender, and dosage.

References